AREC.L

Arecor Therapeutics
Arecor Therapeutics - Arecor to present on Investor Meet Company
27th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9019F
Arecor Therapeutics PLC
27 September 2024
 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

Arecor to present on Investor Meet Company platform

 

Cambridge, UK, 27 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer, will be providing a live presentation of the Group's recently announced interim results for the six months ended 30 June 2024 via the Investor Meet Company platform, on Thursday 3 October at 3pm BST.

 

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard up until 9am BST on Wednesday 2 October 2024, or at any time during the live presentation.

 

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:

https://www.investormeetcompany.com/companies/arecor-therapeutics-plc

 

Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

 

 

-ENDS-

For more information, please contact:

 

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com



Panmure Liberum Limited (NOMAD and Joint Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

 



WG Partners LLP (Joint Broker)


Nigel Barnes, Satheesh Nadarajah

David Wilson, Claes Spang

Tel: +44 (0)203 705 9321



ICR Consilium


Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com



 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

 

For further details please see our website, www.arecor.com

 

-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNRARSVUKUUR]]>
TwitterFacebookLinkedIn